IntroductionThe CO2 laser has experienced a revival since the introduction of the fractional technology. The Fraxis® CO2 laser is a new high potential CO2 laser. The aim of our study was to determine the main indications and frequency of use in a dermatologist office.
MethodMonocentric retrospective study conducted over a period of 2 months. The inclusion criteria were: patients who benefited from a treatment with CO2 laser in continuous, pulsed or fractional mode for an indication validated by at least one publication. The exclusion criteria were indications uncommitted. The laser used was the Fraxis® CO2 laser (Ilooda, Korea) emitting at 10600 nm and based on a RF excited laser tube technology developed by Synrad company (USA).